TARGETED AGENT AND PROFILING UTILIZATION REGISTRY STUDY

Where can I learn more?
Visit the TAPUR study website at www.TAPUR.org to learn more about the study including:

- Information on eligibility for study
- Latest news and study announcements
- List of drugs available in the study
- Up-to-date list of study sites

Questions?
We’d love to hear from you. Contact the study team:

For general questions, email us at TAPUR@asco.org.
To speak with a site representative, go to Participating Centers page on the study website.

www.ClinicalTrials.Gov Identifier:
NCT02693535

About ASCO
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents oncology professionals who care for people living with cancer.

Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Learn more at www.ASCO.org and explore patient education resources at www.Cancer.Net.
What is the TAPUR study and why is it being conducted?

The Targeted Agent and Profiling Utilization Registry (TAPUR) study is a clinical trial for people with advanced cancer whose cancer is no longer responding to standard treatment or for whom there is no standard treatment available.

A patient’s cancer must also have a potentially actionable genomic variant already identified through a genomic test (contact a participating TAPUR site for more information).

The TAPUR study aims to:

- Learn whether approved drugs might work against different cancers
- Find out how genomic or molecular tests are used to care for people with advanced cancer
- Use the study results to help inform future studies and aid in the care of people with cancer
- Provide patients with access to therapies which may benefit them
- Provide patients with access to therapies which may benefit them

Am I eligible?

Talk with your doctor about your treatment options, including clinical trials. If you agree with all of the below statements, you may be eligible for the TAPUR study.

- I am at least 18 years old.
- I am not currently pregnant and do not plan to become pregnant soon.
- I have an advanced cancer (including solid tumors, multiple myeloma, and B cell non-Hodgkin lymphoma).
- My cancer is no longer responding to standard anti-cancer treatment, or there is no standard treatment available for my cancer.
- I have had a genomic or molecular profiling test performed on my cancer.
- I am out of bed and active at least half of each day.

All drugs in the TAPUR study are approved by the Food and Drug Administration (FDA) for treatment of cancer.

For more information on the study, please visit www.TAPUR.org.

What does the study involve?

If you are eligible for the TAPUR study and decide to participate:

- Your doctor will determine which therapy is best for you based on the results of a genomic test performed on your cancer. Although all of the drugs in the TAPUR study are approved by the FDA for at least one type of cancer, the therapy you would receive has not yet been approved for your specific type of cancer.
- You will receive the study drug, an FDA-approved targeted anti-cancer therapy, at no cost to you.
- The TAPUR study will act in coordination with your routine clinical care visits performed by your doctor to monitor your health. At some of these visits, you will be evaluated to determine whether your cancer is responding to the therapy. Some participants may need to go to the doctor’s office more frequently.

Participating sites

The TAPUR study is available at cancer centers and clinics throughout the United States. Visit our website at www.TAPUR.org to see the full list of sites where patients may enroll in TAPUR.

Additional sites will be brought on throughout the study, please check the website frequently for updates.